FEASIBILITY, SAFETY AND OUTCOMES WITH DIFFERENTIAL SPOT SPACING PATTERNS IN EYES UNDERGOING SMILE FOR MYOPIA CORRECTION- A CONTRALATERAL EYE STUDY - DSPSM

DR SRI GANESH0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Patients with Simple Myopia and Myopic Astigmatism
•2.Age ( 21-40 years) with no lens changes due to cataract.
•3.SEQ difference of 2 D or less between 2 eyes
•4.Manifest spherical equivalent - 10 diopters or less
•5.Manifest cylinder 1 diopters or less
•6.Stable refraction, < 0.50 D change in last 1 year
•7.Best spectacle corrected visual acuity of 6/6 or better in both eyes
•8.No evidence of irregular astigmatism on corneal topography in both eyes
•9.Residual stromal bed thickness (RSBT) â?? at least 280 Âµm
•10.Ability to understand and willing to sign inform consent, to participate in followups

•1.Patients having Pure Presbyopia.
•2.Patients having hypermetropia, mixed astigmatism with Presbyopia.
•3.Eyes in which corneal marking is performed for significant astigmatism( 1D or more)
•4.Patients who have undergone any refractive procedure previously.
•5.Patients who have undergone cataract surgery.
•6.Patients having High Myopia ( >10 D)/ SE > 10D.
•7.Anisometropia of 2D or more
•8.Amblyopia
•9.Progressive or unstable myopia and /or astigmatism
•10.Endothelial cell count < 1500 cells/mm2
•11.Evidence of ocular surface diseases
•12.History of ocular surgery, severe dry eye , corneal degeneration , corneal dystrophy, cataract , uveitis, retinal pathology
•13.Kerato-ectatic conditions such as Keratoconus, Keratoconus suspects, Pellucid marginal degeneration etc
•14.Concurrent use of medication likely to affect interface healing
•15.Immunocompromised state / pregnancy / nursing mothers/ cancer patients

发起方

DR SRI GANESH